




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5

6 / 22

600




Figure 6A

SUBSTITUTE SHEET (RULE 26)

7 / 22




Figure 6B

SUBSTITUTE SHEET (RULE 26)

8 / 22




Figure 7A

SUBSTITUTE SHEET (RULE 26)

9 / 22

A

770

LINES OF THERAPY			
	START DATE	END DATE	THERAPIES
771	09-06-97	11-01-97	DRUG A
772	11-01-97	12-12-97	DRUG B
773	06-15-98	07-22-98	MED PROC C
			DRUG D

Figure 7B

10 / 22




Figure 7C

SUBSTITUTE SHEET (RULE 26)




Figure 8




Figure 9

Cancer Type	Guardant360 (Plasma)		Tissue Experience ²⁻⁵
	Patients Accessed (n)	MSI-H Detected	
Colorectal	15466	426 (3%)	5 - 7.2%
Gastric/Esophageal	2906	105 (4%)	1.6 – 4.3%
Pancreatic	9760	58 (1%)	NA – 1.2% ²
Hepatocellular Carcinoma	1399	10 (2%)	0.8 – 2.7%
Cholangiocarcinoma	120	2(1%)	NA – 1.4%
Total	29651	601 (2%)	

NA = Not available/reported across all studies

Figure 10

14/22




Figure 11




Figure 12




Figure 13

17/22




Figure 14

18/22




Figure 15

SUBSTITUTE SHEET (RULE 26)

19/22




Figure 16

20/22




Figure 17




Figure 18




Figure 19

SUBSTITUTE SHEET (RULE 26)